Azione PEG A PHARMA EQUITY GROUP A/S
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Pharma Equity Group A/S

Azioni

PEG A

DK0061155009

Mercato chiuso - Nasdaq Copenhagen
Altri mercati azionari
 17:20:02 17/07/2024 		Variaz. 5gg Var. 1 gen.
0,31 DKK -0,64% Grafico intraday di Pharma Equity Group A/S +5,44% -27,91%
17/05 Pharma Equity Group A/S riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024 CI
16/05 Pharma Equity Group A/S mantiene la guidance sugli utili del gruppo per l'intero anno 2024 CI

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
The Board of Directors' decision to issue convertible loans
Major shareholder announcement - Pharma Equity Group A/S
Major shareholder announcement - Pharma Equity Group A/S
Results of extraordinary general meeting in Pharma Equity Group A/S
Pharma Equity Group A/S Reports Earnings Results for the First Quarter Ended March 31, 2024
The Board of Director's decision to issue convertible loans
Pharma Equity A/S : 2024 Q1 Consolidated Interim Report
Consolidated interim report 1 January – 31 March 2024
Pharma Equity Group A/S Maintains Group Earnings Guidance for the Full Year of 2024
Pharma Equity Group A/S announced that it expects to receive DKK 1 million in funding
Exploration of options regarding a directed capital increase at market price in Pharma Equity Group A/S
Notice convening the extraordinary general meeting of Pharma Equity Group A/S
Major shareholder announcement - Pharma Equity Group A/S
Passing of the General Meeting of Pharma Equity Group A/S
The Board of Director's decision to issue convertible loans
Pharma Equity Group A/S announced that it has received DKK 7.6 million in funding
Pharma Equity A/S : Group's subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company's patented drug candidate RNX-051.
Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s patented drug candidate RNX-051.
Pharma Equity Group?s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company?s patented drug candidate RNX-051
Notice convening the annual general meeting in Pharma Equity Group A/S
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione PEG A
  4. Notizie Pharma Equity Group A/S
  5. Altre lingue